Clinical trial readout dates for Harmony Biosciences Holdings Inc., compiled from ClinicalTrials.gov, alongside the SEC filings where results are announced. The next expected readout is April 2027.
| Phase 3 Pitolisant tablet Prader-Willi Syndrome · NCT06366464 | April 2027 Recruiting |
| Phase 3 HBS-301 tablet Idiopathic Hypersomnia · NCT07500090 | October 2027 Recruiting |
| Phase 3 HBS-301 EDS; Cataplexy · NCT07675135 | October 2027 Recruiting |
| Phase 3 Pitolisant Prader-Willi Syndrome · NCT07219485 | August 2030 Enrolling |
Harmony Biosciences Holdings Inc. reported $1.05B in cash, cash equivalents and marketable securities at Sep 30, 2026 (10-Q filed 2026-11-04). It reported net income of $48M for that quarter.
| 8-K Reg FD Disclosure — often a data announcement | 2026-11-04 |